Rajesh Nambiar, MD
Cardiovascular Disease · Amarillo, TXNPI 1760649289
Payments from drug & device makers
Across 665 payments — averaging $862.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- CSL Behring$162K
- Janssen Research & Development, LLC$150K
- Boehringer Ingelheim International GmbH$110K
- Johnson & Johnson$64K
- Boehringer Ingelheim Pharma GmbH & Co.kg$63K
- Abbott$10K
- plus $14K from 28 others
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| CSL Behring | 24 | $161,839 |
| Janssen Research & Development, LLC | 27 | $150,421 |
| Boehringer Ingelheim International GmbH | 83 | $110,248 |
| Johnson & Johnson | 80 | $64,035 |
| Boehringer Ingelheim Pharma GmbH & Co.kg | 13 | $63,400 |
| Abbott | 197 | $10,276 |
| AstraZeneca | 21 | $5,727 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 10 | $2,383 |
| Medtronic(2 entities) | 30 | $1,192 |
| Boston Scientific | 19 | $697 |
| Novartis | 32 | $682 |
| Abiomed | 11 | $597 |
| E.r. Squibb & Sons, L.L.C. | 31 | $401 |
| Amarin Pharma, Inc. | 16 | $267 |
| Amgen | 19 | $260 |
| Pfizer | 6 | $188 |
| Biotronik Inc. | 2 | $163 |
| Cordis US CORP. | 2 | $140 |
| Atricure, Inc. | 1 | $137 |
| Merck | 7 | $132 |
| Novo Nordisk | 7 | $123 |
| Tactile Systems Technology Inc | 6 | $104 |
| Boehringer Ingelheim | 4 | $62 |
| Bayer | 3 | $49 |
| Lexicon Pharmaceuticals, Inc. | 3 | $45 |
| Cook Medical LLC | 1 | $39 |
| Philips North America LLC | 2 | $37 |
| Penumbra, Inc. | 1 | $31 |
| Edwards Lifesciences | 2 | $30 |
| Daiichi Sankyo Inc. | 1 | $22 |
| Angiodynamics, Inc. | 1 | $20 |
| Cardinal Health 200 LLC | 1 | $20 |
| Alnylam Pharmaceuticals Inc. | 1 | $18 |
| Esperion Therapeutics, Inc. | 1 | $17 |
How this compares
$573,801 in reported general payments places this provider in the 95th percentile of 1,515 cardiovascular disease providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other cardiovascular disease in Amarillo
- David BrabhamAmarillo$11.5M
- Alfred ChuAmarillo$1.3M
- Joaquin Martinez Arraras CaroAmarillo$1.2M
- Ramin Farzaneh-FarDallas$17.1M
- Jeffrey GladdenDallas$15.8M
- Ann NavarDallas$14.5M
- Justin GrodinDallas$6.2M
- Christie BallantyneHouston$4.6M
- Syed NaqviHouston$3.6M
- Faisal WahidMcKinney$3.4M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.